AZD5363 in combination with paclitaxel has been utilized in a phase II clinical trial in patients with PIK3CA mutation and PIK3CA amplification in advanced gastric adenocarcinoma. This evidence concerns the gene PIK3CA and gastric adenocarcinoma.